Literature DB >> 24269014

[Clinical aspects of brain metastases from nasopharyngeal carcinoma].

F Elloumi1, M Ben Amor, L Ghorbel, H Mnif, T Boudawara, A M Ghorbel, M Frikha, J Daoud.   

Abstract

Metastasis to the central nervous system, either through a hematogenous route or through the cerebrospinal fluid, is extremely rare in nasopharynx cancer. We aim to expose clinical aspects, therapeutic features and prognosis of nasopharyngeal carcinoma with brain metastases. We retrospectively reviewed the medical history of about 420 patients with nasopharyngeal carcinoma treated during 17 years at the university hospital of Sfax (Tunisia). Among them, three patients had brain metastasis. We excluded patients with direct extension to the brain. Tumours of the nasopharynx were locally advanced. The first patient had brain metastases at the initial diagnosis. The two other patients had brain metastases at 10 and 16 months during the follow-up. Ocular signs were the symptoms. Lesions were unique in two patients. Synchronous bone metastases were recorded in the three cases. All patients had whole brain radiation therapy and palliative chemotherapy. All patients had a progression of the disease and died. Brain metastases in nasopharynx cancer represent a rare event. Prognosis is poor, depending on age, surgical excision and synchronous metastases. Survival does not exceed 6 months.
Copyright © 2013 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Brain; Carcinoma; Carcinome; Cerveau; Metastasis; Métastase; Nasopharynx

Mesh:

Substances:

Year:  2013        PMID: 24269014     DOI: 10.1016/j.canrad.2013.09.004

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  1 in total

1.  Long-term recurrence and brain metastasis of nasopharyngeal carcinoma mimicking cystic radiation encephalopathy relapse: a case report.

Authors:  Xuhui Chen; Lijie Ren; Guozhen Qiu; Liming Cao
Journal:  BMC Neurol       Date:  2021-02-08       Impact factor: 2.474

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.